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Abstract: Tumor hypoxic microenvironment causes hypoxia inducible factor 1 alpha (HIF-1α)
activation and necrosis with alarmins release. Importantly, HIF-1α also controls the expression of
alarmin receptors in tumor cells that can bind to and be activated by alarmins. Human tumor tissues
possess 1–2% of cancer stem cells (CSCs) residing in hypoxic niches and responsible for the metastatic
potential of tumors. Our hypothesis is that hypoxic CSCs express alarmin receptors that can bind
alarmins released during necrosis, an event favoring CSCs migration. To investigate this aspect,
glioblastoma stem-like cell (GSC) lines were kept under hypoxia to determine the expression of
hypoxic markers as well as receptor for advanced glycation end products (RAGE). The presence of
necrotic extracts increased migration, invasion and cellular adhesion. Importantly, HIF-1α inhibition
by digoxin or acriflavine prevented the response of GSCs to hypoxia alone or plus necrotic extracts.
In vivo, GSCs injected in one brain hemisphere of NOD/SCID mice were induced to migrate to the
other one in which a necrotic extract was previously injected. In conclusion, our results show that
hypoxia is important not only for GSCs maintenance but also for guiding their response to external
necrosis. Inhibition of hypoxic pathway may therefore represent a target for preventing brain invasion
by glioblastoma stem cells (GSCs).
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1. Introduction
Cancer onset and progression cannot be considered a simple accumulation of mutations but a
more complex process involving a wide number of molecules regulating metabolism, survival and
cell proliferation [1]. In particular, the interplay between the growing cancer and its surrounding
microenvironment plays a central role in influencing cancer cell behavior [2]. In this context, it is
important to consider that cancer cells live in a hostile microenvironment characterized by low oxygen
rate (around and below 2%) [3]. This particular condition promotes the expression of the hypoxia
inducible factor 1 (HIF-1), a master key transcription factor [4]. Indeed, intratumoral hypoxia and HIF-1
are a common finding in human cancer. In particular, HIF-1 regulates processes such as angiogenesis,
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metabolic reprogramming, extracellular matrix remodeling, epithelial-mesenchymal transition, motility,
invasion, iron homeostasis, metastasis, CSC maintenance, immune evasion, resistance to chemotherapy
and radiation therapy [5]. In the case of metabolic reprogramming, hypoxia and HIF-1α induce
expression of Hexokinase 2 (HK2) [6]. In both normal and cancer cells, hexokinase (HK), uses ATP
to regulate the irreversible phosphorylation of glucose to glucose-6-phosphate that cannot leave the
cell and is utilized as fuel for different metabolic pathways [7]. However, in cancer cells, hypoxia and
other epigenetic changes, increase expression of the isoform HK2 that translocates to the mitochondria
associating with components of the mitochondria permeability Transition Pore (MPTP) with the aim
to efficiently produce glucose-6-phosphate for glycolysis and prevent release of cytochrome c from
the mitochondria thereby inhibiting apoptosis [7]. In fact, a large number of tumors is characterized
by HK2 overexpression and inhibitors of HK2 are under study as anticancer agents [8]. HIF-1 is
a heterodimeric protein composed of a constitutively expressed β subunit and an O2-regulated α
subunit. Under normoxic conditions, the HIF-1α subunit is synthesized and hydroxylated on proline
residue 402 and/or 564 by specific prolyl hydroxylase domain (PHD) proteins (i.e., PHD2) using O2 and
α-ketoglutarate as substrates to catalyze a dioxygenase reaction in which one oxygen atom is inserted
into the proline residue and the other oxygen atom is inserted into α-ketoglutarate to form succinate
and CO2. Next, the protein osteosarcoma-9 (OS-9) interacts with both PHD2 and HIF-1α, promoting
hydroxylation [9]. This step is essential for the binding of the von Hippel-Lindau protein (VHL) that
interacts with Elongin C and thereby recruits a ubiquitin ligase complex. This process leads HIF-1α to
be degraded by the proteasome. Differently, under hypoxic conditions, the oxygen deprivation inhibits
the hydroxylation reactions and/or increases mitochondrial production of Reactive Oxygen Species
(ROS), which may inhibit the hydroxylases by oxidizing a ferrous ion in the catalytic site. In this
way the stability and transactivation function of HIF-1α are increased, promoting dimerization with
HIF-1β. Afterwards, this dimerization determines the activation of the complex and the consecutive
binding to its recognition Hypoxia Response Elements (HRE) sequence 5′-(A/G)CGTG-3′ in target
genes, thus increasing transcription [10,11]. Along with HIF-1 activation, hypoxic microenvironment
induces necrotic cell death with release of intracellular components many of which act as damage
associated molecular patterns (DAMPs) or alarmins [12]. Alarmins include ATP, proteins such as high
mobility group box 1 (HMGB1), phosphatidylserine, etc. and are one of the causes of tumor-associated
inflammation [13]. In fact, alarmins are “sensed” by immune, cancer, dendritic and other cells
by binding to membrane receptors such as receptor for advanced glycation end products (RAGE),
Toll Like Receptors (TLRs) and others [14]. In particular, RAGE is a plasma membrane receptor
capable of recognizing molecular patterns on proteins such as HMGB1, S100 and β-fibrils [15,16].
Once activated, RAGE triggers a pro-inflammatory and reparative cascade involving transcription
factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) [17]. Moreover,
by using tumor cell lines and Glioblastoma (GBM) tumor biopsies we have already demonstrated an
HIF-dependent increase in RAGE expression [18]. Importantly, HIF-1 activation and alarmin release
must not be considered as two separate and independent events. HIF-1-expressing and surviving
cancer cells increase expression of alarmins receptors on their plasma membrane [19,20]. The binding
of alarmins to plasma membrane receptors activates a signaling cascade that ends with the activation
of the transcription factor NF-kB. At this point, cancer cells, through HIF-1 and NF-kB activation,
reprogram molecular pathways of metabolism, ROS production/scavenging, autophagy, apoptosis,
etc., increasing survival and resistance to stress and acquiring a more aggressive phenotype promoting
tumor progression [21]. Another important and recently discovered aspect of tumors is the presence of
cancer stem cells (CSCs) [22]. Importantly, CSCs reside and thrive in the hypoxic niches [23]. Indeed,
hypoxia would serve as a stimulus to maintain stemness of CSCs. Moreover, CSCs represent the
most resistant tumor cell population responsible for tumor relapse and metastasis [24]. Since the CSC
paradigm has been developed, a number of data supporting their ability to promote tumor growth have
been collected concerning different kinds of tumors such as cerebral [25], pulmonary [26], colon [27],
ovary [28], pancreas [29], prostate [30] and thyroid [31], in addition to many other neoplasms, both
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solid and belonging to the immune-hematopoietic system [32]. However, a study detailing the effect of
hypoxia, inflammation and alarmins released during necrosis on CSCs is still missing. Glioblastoma is
a deadly brain tumor with a high degree of heterogeneity [33]. CSCs are present in glioblastoma in
different percentages and are thought to be responsible for therapy resistance and tumor resilience [34].
Moreover, the possibility to isolate and grow, in vitro, CSCs from glioblastoma biopsies (GSCs)
correlates with worse progression free survival [35]. Among GSCs that have been isolated and grown
in vitro, two different clusters have emerged based on gene expression profiling, i.e., proneural-like,
full stem phenotype (GSf-like) in which cells grow as neurospheres and mesenchymal-like, restricted
stem phenotype (GSr-like) characterized by adherent growth in vitro [36]. In vivo, GSf-like phenotype
shows a higher invasiveness than GSr-like phenotype [37].
To this direction, our hypothesis is that CSCs respond to hypoxia by increasing alarmins receptors
that can bind to alarmins released by necrotic cells. By using different GSC lines, we aim to demonstrate:
i) response to hypoxia by determining HIF-1α and HIF-1α-dependent gene and protein expression of
vascular endothelial growth factor (VEGF) and Hexokinase (HK2); ii) gene and protein expression of
alarmin receptor RAGE. Moreover, we also aim to show that, in the presence of a necrotic extract rich
in alarmins, GSCs increase their invasion and adhesion capacity both in in vitro and in in vivo settings.
2. Results
2.1. HIF-1α and HIF-1α-Dependent Gene Expression in GSCs
To study how GSCs respond to hypoxia, we selected four different GSC cell lines named #1, 61,
83 and 163. These GSC lines were previously isolated and characterized [38]. In particular, we first
determined HIF-1α, VEGF and HK2 mRNA and protein expression under normoxic and hypoxic
conditions. Figure 1 shows mRNA levels during a time course of 2, 4, 24 and 48 h for HIF-1α, HK2 and
VEGF under normoxia (N) and hypoxia (H) for the four GSC lines.
In the case of GSC #1, an increase in HIF-1α mRNA was observed after 48 h of hypoxia whereas
VEGF and HK2 increased at 24 h and 48 h (Figure 1A). No mRNA increase for HIF-1α was observed
after hypoxia for GSC #61 whereas, VEGF and HK2 mRNA increased after 4 and 24 and 4, 24 and 48 h,
respectively. (Figure 1B). In GSC #83 we observed an increase in mRNA expression for HIF-1α after
4 h of hypoxia. VEGF mRNA showed an increase during hypoxia treatment whereas HK2 mRNA
increased after 4, 24 and 48 h of hypoxia (Figure 1C). Finally, in GSC #163, we, again, did not observe
an increase of HIF-1α mRNA. By contrast, we observed a mRNA increase for VEGF following 4 and
24 h hypoxia and for HK2 after 4, 24 and 48 h of hypoxia (Figure 1D). These results were confirmed by
measuring protein expression by Western blot. As shown in Figure 2A, GSC #1 responded to hypoxia
by increasing HIF-1α protein, an effect that started after 4 h and continued up to 48 h.
The increase of HK2 and VEGF was instead significant after 24 and 48 h of hypoxia (Figure 2A).
GSC #61 showed an increase of HIF-1α protein after 4 h of hypoxia that continued at 24 and 48 h
(Figure 2B). This was accompanied by an increase of HK2 after 24 and 48 h of hypoxia. However,
no changes for VEGF were measured (Figure 2B). GSC #83 showed an increase in HIF-1α expression
after 4, 24 and 48 h of hypoxia. HK2 expression increased after 24 and 48 h of hypoxia (Figure 2C).
No change for VEGF was observed. Finally, also for GSC #163 we observed an increase of HIF-1α from 4
to 48 h and an increase of HK2 that started at 24 h and was maintained after 48 h of hypoxia (Figure 2D).
Again, VEGF did not show any change in expression. Altogether, these data show that the four GSCs
respond to hypoxia by stabilizing HIF-1α protein during the first 4 h. However, such a response is
sustained by de novo HIF-1α protein synthesis when hypoxia is prolonged up to 24 h. On the other
hand, HIF-dependent genes herewith investigated are upregulated starting at 24 h hypoxia exposure
and show differences in expression among the four GSCs.
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Figure 1. Hypoxia regulation of hypoxia inducible factor 1 alpha (HIF-1α), vascular endothelial 
growth factor (VEGF) and Hexokinase 2 (HK2) mRNA expression in glioblastoma stem-like cells 
(GSCs). (A–D) GSCs #1, 61, 83 and 163 were grown as indicated in Materials and Methods. Cells were 
then counted and plated (5 × 105) in ultra-low attachment 6-well plates and either kept in normoxic 
or hypoxic condition for the times indicated. Fold increase of HIF-1α, VEGF and HK2 mRNA under 
hypoxia were determined by RT-PCR. Experiments in the figure were repeated three times. * 
Significantly different from the corresponding control normoxic cells. Significance was set at p < 0.05. 
n, normoxic cells; h, hypoxic cells. 
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Figure 1. Hypoxia regulation of hypoxia inducible factor 1 alpha (HIF-1α), vascular endothelial
growth factor (VEGF) and Hexokinase 2 (HK2) mRNA expression in glioblastoma stem-like cells
(GSCs). (A–D) GSCs #1, 61, 83 and 163 were grown as indicated in Materials and Methods. Cells
were then counted and plated (5 × 105) in ultra-low attachment 6-well plates and either kept in
normoxic or hypoxic condition for the times indicated. Fold increase of HIF-1α, VEGF and HK2 mRNA
under hypoxia were determined by RT-PCR. Experi ents in the figure were repeated thre times.
* Significantly different from the corresponding control normoxic cells. Significance was set at p < 0.05.
n, normoxic cells; h, hypoxic cells.
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Figure 2. Hypoxia increases expression of HIF-1α, VEGF and HK2 in different GSC lines. (A–D) GSCs 
#1, 61, 83 and 163 were kept under normoxia or hypoxia for the time indicated and then processed to 
obtain whole cell lysates. HIF-1α, VEGF and HK2 protein expression levels were determined by 
Western blot as indicated in Materials and Methods. Densitometric analysis of the gels was performed 
by Image J software as indicated in Materials and Methods. Cyclin-dependent kinase 4 (CDK4) was 
used as loading control. Experiments in the figure were repeated three times. * Significantly different 
from the corresponding control normoxic cells. Significance was set at p < 0.05. n, normoxic cells; h, 
hypoxic cells. 
The increase of HK2 and VEGF was instead significant after 24 and 48 h of hypoxia (Figure 2A). 
GSC #61 showed an increase of HIF-1α protein after 4 h of hypoxia that continued at 24 and 48 h 
(Figure 2B). This was accompanied by an increase of HK2 after 24 and 48 h of hypoxia. However, no 
changes for VEGF were measured (Figure 2B). GSC #83 showed an increase in HIF-1α expression 
after 4, 24 and 48 h of hypoxia. HK2 expression increased after 24 and 48 h of hypoxia (Figure 2C). 
No change for VEGF was observed. Finally, also for GSC #163 we observed an increase of HIF-1α 
from 4 to 48 h and an increase of HK2 that started at 24 h and was maintained after 48 h of hypoxia 
(Figure 2D). Again, VEGF did not show any change in expression. Altogether, these data show that 
the four GSCs respond to hypoxia by stabilizing HIF-1α protein during the first 4 h. However, such 
a response is sustained by de novo HIF-1α protein synthesis when hypoxia is prolonged up to 24 h. 
Figure 2. Hypoxia increases expression of HIF-1α, VEGF and HK2 in different GSC lines. (A–D) GSCs
#1, 61, 83 and 163 were kept under normoxia or hypoxia for the time indicated and then processed
to obtain whole cell lysates. HIF-1α, VEGF and HK2 protein expression levels were determined by
Western blot as indicated in Materials and Methods. Densitometric analysis of the gels was performed
by Image J software as indicated in Materials and Methods. Cyclin-dependent kinase 4 (CDK4) was
used as loading control. Experiments in the figure were repeated three times. * Significantly different
from the corresponding control normoxic cells. Significance was set at p < 0.05. n, normoxic cells;
h, hypoxic cells.
2.2. Hypoxia-Dependent Expression of the Alarmin Receptor RAGE
Our next step was to measure the expression of RAGE in the four GSCs under normoxic and
hypoxic conditions. As stated before, RAGE was chosen because of our previous studies confirming
an HIF-dependent increase in RAGE expression [18]. As shown in Figure 3, compared to the normoxic
control, RAGE expression increased after 24 of hypoxia in two of the four GSCs examined, namely in
GSCs #1 and #83.
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Figure 3. Hypoxia regulation of receptor for advanced glycation end products (RAGE) mRNA
expression in GSCs. GSCs #1, 61, 83 and 163 were grown as indicated in Materials and Methods.
Cells were then counted and plated (5 × 105) in ultra-low attachment 6-well plates and either kept
in normoxic or hypoxic condition for the times indicated. Aft rward, fold increase of RAGE mRNA
under hypoxia was determined by RT-PCR. Experiments in the figure w re repeated three times.
* Significantly different from the corresponding control normoxic cells. Significance was set at p < 0.05.
n, normoxic cells; h, hypoxic cells.
Therefore, considering the results of Figure 1; Figure 2 we decided to continue the studies by
using GSCs #1 and 83. To study HIF-1α-dependent RAGE expression, GSCs #1 and 83 were kept under
normoxic or hypoxic conditions in the presence or absence HIF-1α inhibitors. In fact, several natural
and synthetic compounds have been discovered and used to inhibit HIF [39]. Among those, herewith,
we choose Digoxin and Acriflavine that have been shown to prevent HIF-1α protein synthesis and
dimerization, respectively [40,41]. Resu ts of these experiments are epor ed in Figure 4 showing an
increase of RAGE expression under hypoxia that was prevented by treating GSC #1 with 100 nM
Digoxin and 5 µM Acriflavine and GSC #83 with 200 nM Digoxin and 10 µM Acriflavine. The results
shown in Figure 4 have been summarized in Table 1 where we reported the mean fluorescent intensity
per cell. It must be noted that the reduction of RAGE fluorescent observed after treating hypoxic GSCs
with either Digoxin or Acriflavine in most probably due to the combined effect of both a reduction of
RAGE expression and of the number of cells. In fact, as also observed by us (not shown) and previously
reported, both Digoxin and Acriflavine reduce tumor cell growth both in vitro and in vivo [40,41].
The different doses were determined following previous published results on other cancer cell
lines [40,41] and by treating GSCs #1 and #83 with Digoxin from 50 to 200 nM and with Acriflavine
from 2.5 to 10 µM and measuring HIF-1α expression as shown in Supplementary Figure S1. Moreover,
Figure 4 shows: (i) the different growth behavior of GSC #83 compared to GSC #1 that also justify
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the different doses of Digoxin and Acriflavine used in order to reach the center of the neurosphere;
(ii) the uneven and patched cellular distribution of RAGE in the cells after hypoxia treatment.
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Figure 4. Hypoxia-induced RAGE expression is prevented by HIF-1α inhibition. (A) GSC #1 was
grown on glass coverslips as indicated in Materials and Methods. Afterward, cells were kept under
normoxia or hypoxia for 24 h in the presence or absence of 100 nM Digoxin and 5 µM Acriflavine and
then processed for RAGE immunofluorescence staining as indicated in Materials and Methods. Images
were taken with a Zeiss LSM 510 confocal microscope (Magnification 60×). (B) GSC #83 was grown on
glass coverslips as i dicated in Materials and Methods. Afterward, cells were kept under normoxia
or hypoxia for 24 h in the presence or absence of 200 nM Digoxin and 10 µM Acriflavine and then
processed for RAGE immunofluoresc nce taining s indicated in Mater als a d Methods. Images w re
take with a Zeis LSM 510 confocal microscope (Magnification 60×).
Table 1. Mean fluorescent intensity per cell calculated by dividing total fluorescence intensity by
the number of cells from at least three separate experiments including the one shown in Figure 4.
*, significantly different from untreated sample. Significance was set at p < 0.05. C, control cells.
GSC #1 GSC #83
Normoxia (mean fluorescence intensity per cell) Normoxia (mean fluorescence intensity per cell)
C 75.3 ± 6.5 C 50.7 ± 5.0
Digoxin 100 nM 70.7 ± 5.7 Digoxin 200 nM 56.7 ± 4.0
Acriflavine 5 µM 66.3 ± 5.7 Acriflavine 10 µM 60.3 ± 2.3
Hypoxia (mean fluorescence intensity per cell) Hypoxia (mean fluorescence intensity per cell)
C 92.3 ± 6.5 C 107 ± 9.8
Digoxin 100 nM 56.0 ± 4.6 * Digoxin 200 nM 64.3 ± 4.7 *
Acriflavine 5 µM 32.0 ± 2.6 * Acriflavine 10 µM 74.7 ± 4.6 *
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2.3. GSC Migration and iInvasion in the Presence of Necrotic Extracts
The increased RAGE expression observed under hypoxia, could serve in GSCs as a receptor
for “sensing” the presence of a necrotic stimuli coming from cells dying because of reduced oxygen
tensions. To this effect, we performed migration and invasion assays. In these experiments, GSCs were
kept under normoxic and hypoxic conditions in the presence or absence of HIF-1α inhibitors digoxin
or acriflavine as previously described. Afterward, cells were plated in invasion chambers as described
under Methods. Necrotic extracts were placed in the lower side of the chamber as a chemo-attractant
to stimulate cellular invasion. Results are reported in Figure 5A and show a different behavior between
GSCs #1 and #83.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 9 of 24 
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was then incubated for 24 h in normoxic (N) or hypoxic (H) condition in the presence or absence
of digoxin or acriflavine. Moreover, a necrotic extract (1 µg/mL) was placed at the bottom of each
well. Invading cells were stained as described in Materials and Methods and then visualized with an
optical microscope and counted. Graph represents the percentage of invading cells from a total of
150.000. C, control untreated cells; D, Digoxin, A, Acriflavine. Experiments in the figure were repeated
three times. * Significantly different from the corresponding control normoxic cells. # Significantly
different from the corresponding control normoxic or hypoxic cells. Significance was set at p < 0.05.
(B) Human umbilical vein endothelial cells (HUVEC) were stained with Calcein Red AM and seeded
on a glass coverslip in the presence or absence of a necrotic extract for 24 h as described in Materials
and Methods. Afterward, GFP-GSCs #1 and 83, previously kept under hypoxia in the presence or
absence of Digoxin and Acriflavine, were plated on such a layer. After 24 h, non adherent GFP-GSCs #1
and 83 were removed by extensive washing. GFP-GSC were then visualized by confocal microscopy
(Magnification 60×). Images were then taken and analyzed by Image J software. Experiments in the
figure were repeated three times. * Significantly different from the corresponding normoxic or hypoxic
control cells. Significance was set at p < 0.05. C, control untreated cells; D, Digoxin, A, Acriflavine;
E, Necrotic Extract.
In fact, in GSC #1 we observed a decrease of the percentage of invading cells under hypoxia
compared to normoxia. Importantly, HIF-1α inhibition by digoxin or acriflavine inhibited GSC invasion
both in normoxic and hypoxic conditions. By contrast, in GSC #83 hypoxia increases migration and
invasion compared to normoxia. Again, Digoxin and Acriflavine inhibited migration and invasion
of GSC #83 but only in hypoxic conditions (Figure 5A). Next, we also assessed the ability of GSCs
to adhere to HUVEC cells in a co-culture experiment. For this experiment, we used GFP-GSCs
whereas HUVEC were stained with Red Calcein-AM. In order to individuate if necrotic cell death
could increase the number of cancer stem cells adhering on a HUVEC substrate, the experiment was
conducted in the presence or absence of necrotic extracts. Moreover, GFP-GSCs were kept under
normoxia or hypoxia for 24 h before proceeding to the co-culture experiment. As shown in Figure 5B,
in normoxia, the presence of a necrotic extract increased the number of GFP-GSC cells attached to
the HUVEC monolayer. Interestingly, the addition of both Digoxin and Acriflavine decreased such a
number. However, when GSCs were kept under hypoxia, the number of adhering cells was higher
than normoxia in particular in the presence of necrotic extracts (Figure 5B). In addition, in this case,
a reduction of adhering GSCs was obtained after treating GSCs #1 and #83 with both Digoxin and
Acriflavine. We also determine if the presence of necrotic extracts and or hypoxia could influence ROS
production in GSCs cells. Figure 6 shows that there were no significant changes in ROS content in both
GSCs #1 and #83 when necrotic extract was added both under normoxia or hypoxia.
Finally, our results on Figure 5 suggest that: (i) when in the presence of a necrotic stimulus, GSCs
increase their invasion and adhesion abilities; (ii) hypoxia increases such a response.
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Figure 6. ROS production in normoxic and hypoxic GSCs. (A,B) GSCs #1 and 83 were seeded in a
6-well plate. The day after, cells were either left untreated or treated necrotic extracts with or without
100 nM digoxin as indicated in the Materials and Methods. Afterward, plates were kept under normoxia
or hypoxia for 24 h. ROS production was assessed by 2′,7′-dichlorfluorescein-diacetate (DCFH-DA)
staining and fluorescence intensity measured by flow cytometry.
2.4. In Vivo GSC Migration
We then examined migration of GSCs through the brain of SCID mice in the presence of necrotic
extracts. In particular, we aimed to test the ability of GSCs to be attracted and to move towards an
inflamed substrate. The steps of the in vivo experiments are schematized in the flow chart of Figure 7.
Initially, we tested the pro-inflammatory effects of 5, 30, 60, 100 ng/5 µL cellular necrotic extracts.
A dose dependent activation of astrocytes, as assessed by Glial fibrillary acidic protein (GFAP)
immunostaining, was detected in the brain region that received the necrotic extracts (Figure 8A,B).
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Figure 8. Astrocytes and microglia activation following in vivo administration of necrotic extracts.
Images of CD1 Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse brains
inoculated in one hemisphere with saline or different concentration of necrotic extracts. (A) Double
immunofluorescence images of brain slices labeled ith an anti-Glial fibrillary acidic protein (GFAP)
antibody (green) and uclei counterstained by echst (blue), show an increase in GFAP labeling,
due to the presence of activated astrocytes, only in the hemispheres receiving the necrotic extract, as
compared with the hemispheres receiving only saline. Scale bar 200 µm. (B) Triple immunofluorescence
images of mouse brain sections stained with anti-GFAP (green) and anti-βTubulin III (red) primary
antibodies and Hoechst as nuclear counters ai . Following he necrotic treatme t, it is possible to
observe a recruitment of activated astrocytes (GFAP + cells) and in some cases of βTubulin III + cells
(white arrow), probably representing resident neural progenitor cells attracted by the necrotic stimulus.
Scale bar 20 µm. (C,D) Double immunofluorescence images of mouse brain sections stained with
anti-Iba1 antibody (green) and Hoechst as nuclear counterstain (blue), show the presence of activated
microglia only in the hemisphere receiving necrotic extracts. Scale bar 20 µm.
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In the same brain region, we observed an increase of ionized calcium binding adaptor molecule-1
(IBA1), suggesting microglia activation in the presence of necrotic extracts (Figure 8C,D). Based on
these results, we choose the concentration of 30 ng/5 µL of necrotic extracts for the brain xenografts.
In these experiments, GFP-GSC #1 cells were injected in the right brain hemisphere. After 8 weeks,
necrotic extracts were injected into the controlateral hemisphere. In control mice, saline solution
was injected in the left brain hemisphere. Collection and analysis of the brains was performed two
weeks later. Extensive tumor growth was observed in the right hemisphere of each inoculated brain
(Figure 9A, left panel), and in the brain hemisphere of the mice treated with the necrotic extracts,
we found an extensive invasion by GFP-GSCs (Figure 9A, left panel).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 14 of 24 
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Figure 9. Brain migration of GFP-GSCs elicited by necrotic extract. GFP-GSC #1 cells were injected
in the right brain hemisphere of CD1 NOD/SCID mice. After 8 weeks, necrotic extracts (30 ng/5 µL)
were injected in the controlateral brain hemisphere. Brain sections were taken two weeks later as
described in Materials and Methods. (A) Triple immunofluorescence images of mouse brain slices
showing inoculated GFP + cells, GFAP + cells and nuclei counterstained with Hoechst. In the left
panel, it is evident the growth of a GFP-GSC #1 tumor mass (green) surrounded by GFAP positive
astrocytes (red). Right panel, the hemisphere, controlateral to the tumor mass, shows an increase in
GFAP labeling only in the presence of necrotic extract (white arrow), as compared to the controlateral
hemisphere receiving saline treatment. Scale bar 200 µm. (B) Triple immunofluorescence images show
an increase of migration, through the anteri i sure, of inoculated GFP-GSC cells from the side
of tumor f mation towards to side receivi ecrotic stim lus. Interestingly, the GFP-GSC cells
have n elongated morphol gy sug estin i ratory behavior and appear surrounde and limited
by GFAP positive cells. Scale bar 20 µ . (C,D) Triple immunofluorescence images of the controlateral
hemisphere show an increase in the number of GFP-GSCs and the presence of Iba1 positive microglia
cells mixed within the migrated tumoral cells. Scale bar 20 µm.
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Interestingly, brain migration was particularly remarkable at the level of the anterior commissure
(about a 5 fold increase in GFP labeling intensity), where GFP-GSCs showed an elongated phenotype,
typical of migrating cells and appeared surrounded by GFAP positive cells (Figure 9A,B). Moreover,
into the controlateral hemisphere, we observed the presence of IBA1 positive cells, mainly distributed
inside the migrated GFP-GSCs mass, as compared to GFAP positive cells (Figure 9C,D). Our results
indicate that the presence of inflammation or necrosis represents a potent stimulus favoring GSC
migration and dissemination inside the brain.
3. Discussion
Hypoxia and necrosis, with subsequent microenvironment inflammation, can be considered two
main features of growing tumors and for this reason, the hypothesis driving this study is that these
two events play a major role in determining the metastatic potential of CSCs present in a tumor.
Thus, in cancer stem cells from a primary tumor, hypoxia may link the expression of genes of the
inflammatory reparative response (IRR) to tumor progression. Therefore, progression of transformed
CSCs does not necessarily require new genetic mutations but can be obtained through a sequential
activation of hypoxia adaptation and proinflammatory genes expression. Several studies recognized
hypoxic microenvironment and HIF-1 activation as fundamental regulators of cellular adjustment
in this particular context [5,42]. Moreover, we and others have previously shown that GBM tumor
biopsies are largely hypoxic, present necrotic areas and have a high HIF-1 and HIF-target genes
expression [18,43–45]. Herewith we studied the response of GSCs to two components of tumor
microenvironment, i.e., hypoxia and necrosis, the latter strictly associated with tissue inflammation.
First of all, our results have shown substantial differences between GSC lines not only in protein
expression but also in mRNA concerning HIF-1 and other important markers such as VEGF or HK2,
confirming the heterogeneity of this kind of tumor [46]. Thus, molecular adaptation to hypoxia has
been assessed in four different human GSCs by RT-PCR and Western blot protein analysis. A significant
increase of HIF-1α and other HIF-1 target genes has been gradually observed. Indeed, in tumor cells,
a great number of adaptations occurs when they are subjected to hypoxia in tumor microenvironment,
and these changes regard metabolism, oxygen distribution, etc. [47,48]. In fact, we documented
modifications of HK2 or VEGF expression especially in line #1 and in line #83 whereas in line #61 and
in line #163, these modifications were less clear. A peculiar behavior was observed in VEGF in line #83.
In fact, in this GSC line, we observed a modulation of VEGF mRNA by hypoxia that was not paralleled
by a modulation of VEGF protein expression (compare Figure 1C with Figure 2C). Even if we did not
investigate into that, we think that such a discrepancy might be due to: (i) a post-transcriptional control
by miRNA that prevent expression of VEGF from mRNA either directly as in the case of miR-16 [49] or
indirectly by targeting VHL protein as in the case of miR-566 [50]; (ii) the intratumoral heterogeneity of
line #83 that contains tumor cells with different metabolic behavior that when sub-cloned gave rise
to cell lines belonging to separate metabolic clusters [51]. In the latter case, this heterogeneity might
reflect in opposite trends of VEGF protein expression showing, on average, no significant increase.
Overall, our results are in accordance with scientific data confirming the main activity of HIF-1 as
master regulator in the complicated process of cellular adaptation to tumor microenvironment [42,48].
However, our interest was in determining the expression of plasma membrane receptor that would allow
GSCs to sense the presence of alarmins or DAMPS released by necrotic cells. To this effect our results
showed that RAGE mRNA and protein levels increased in GSCs following hypoxia exposure. Indeed,
one of the main features of tumor cells is that they live in a hostile microenvironment characterized also
by high levels of inflammation caused by necrosis and subsequent release of alarmins [19]. In order to
survive and thrive in such a microenvironment tumor cells modify, among many other molecules and
pathways, their ability to sense external stimuli and eventually, to migrate towards new sites [52,53].
The expression of RAGE as well as other receptors in the presence of a hypoxic microenvironment
has been observed in many tumors and represents an important step for tumor progression [54,55].
Indeed, immunofluorescence analysis revealed an increased expression and different distribution of
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RAGE as result of hypoxia treatments (Figures 3 and 4). Interestingly, treatment of GSCs with HIF-1
inhibitors such as digoxin and acriflavine, determined a decrease of RAGE expression suggesting a
hypoxia- and HIF-1α-dependency of RAGE in GSCs. In fact, HIF-1α-dependent RAGE expression
has been documented in many pathological situations [55–58]. In addition, hypoxia increases GSCs
migration and invasion toward an attractive stimulus represented by a necrotic extract as well as
their ability to adhere to HUVEC cells (Figure 5). Invasion assays revealed that, at least for GSC
#83, number of invading cells was increased by hypoxia and prevented by digoxin and acriflavine
treatment (Figure 5). On the other hand, our results indicate that GSC-GFP adhesion to a HUVEC
layer is stimulated by hypoxia and further increased if HUVEC are previously treated with a necrotic
extract. In this case, a remarkable difference can be observed between normoxic and hypoxic conditions
with the latter increasing the number of adhering GSCs. Moreover, the addition of necrotic extract
to HUVEC determined an increase of GFP-GSCs (Figure 5). Importantly, digoxin and acriflavine
reduced the number of adhering GFP-GSCs on the HUVEC surface, both in normoxia and in hypoxia
conditions, suggesting a connection between hypoxia, HIF-1α expression and extracellular signals
coming from necrosis as well as necrosis-associated modification of HUVEC. Indeed, modification of
endothelial cells in blood vessels is induced by inflammation associated to necrosis and may represent
an important stimulus for cancer cell adhesion during tumor progression and metastasis formation [59].
In fact, necrosis, inflammation and HIF-1 activation not only promote modifications in cell metabolism
or angiogenesis, but also induce tumor cell invasion [5,60,61]. Hypoxic tumor microenvironment may
be linked to a considerable production of ROS which influences cellular fate. Indeed, high levels of
ROS could determine an interference in the HIF-1 regulation process, promoting the dimerization
of HIF-1α with HIF-1β, leading to a consecutive process activation and binding to HRE in target
genes [62,63]. The increased HIF-1 activation, in turn, determines a constant and progressive alteration
of the environment that leads to a complete destabilization. Thus, we measured ROS levels in GSCs #1
and #83. An important aspect was that the addition of necrotic extracts did not increase ROS levels in
both GSCs #1 and #83 suggesting that this is not the main mechanism. It is worth noting that there is
a strong heterogeneity among GSCs derived from different patients that accounts for differences in
tumor behavior and therapy response [64]. In fact, as previously documented, GSCs #1 and 83 show
different metabolic profiles [51]. Finally, we also performed in vivo analysis to validate our in vitro
results. First, we determined the optimal concentration of necrotic extract sufficient to induce an
inflammation without affecting mouse health. Such a concentration was set at 30 ng/5 µL (Figure 7).
Inflammation was determined by observing increased activation of astrocytes and microglia assessed,
in the mouse brain, through GFAP and IBA1 staining, respectively (Figure 7). Indeed, both GFAP
and IBA1 are considered and used to demonstrate activation of astrocytes and microglia, respectively,
during inflammatory events or diseases such as tubercolus meningitis, astrogliosis, etc. [65,66]. Next,
we proceeded to evaluate if the inflammation stimulus induced by necrotic extracts could influence GSC
migration compared to the saline solution alone. Indeed, after tumor growth, we observed an increase
in GFAP expression only in the brain of mice receiving necrotic extracts (Figure 8). Furthermore, we
also demonstrated cellular specific morphologic modifications tracing GFP-GSCs moving toward
the inflamed controlateral hemisphere probably through the anterior commisure. Finally, a different
distribution of astrocyte and microglia has been revealed. Indeed, GFAP positive cells distributed
around GFP-GSCs whereas IBA1 positive cells were found among GFP-GSCs, probably due to the
different role and interaction with tumor cells of astrocytes and microglia. It is known that inflammation
promotes tumor cell proliferation and increases GBM invasion [67], moreover, inflammation after
surgical resection of GBM can increase tumor progression of remaining tumor cells [68,69].
Limitations and Considerations
We realized that our study was limited by the intrinsic heterogeneity of GSC lines. In fact, in terms
of RAGE expression we noticed that only 2 of them had a significant increase following hypoxia
exposure. In addition, we unraveled differences also between these two selected GSCs. We think that
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the reasons were: (i) the response to hypoxia was different between these two cell lines in term of
HIF-1α protein expression showing, cell line #1, stronger expression than cell line #83; (ii) these two
GSC lines are representative of the two GSC clusters, in particular GSC #1 shows the proneural-like
phenotype (GSf-like) growing as neurospheres in vitro, whereas GSC #83 shows the mesenchymal-like
phenotype (GSr-like) characterized by adherent growth in vitro [36]. It is known that these two
clusters have differential expression of a large number of genes and metabolic profiles [51]. Moreover,
the results on the four GSC first and on the selected two later, indicate the importance of the patient’s
tumor history from transformation to progression and the need for a personalized characterization
that can be achieved not only genetically or metabolically but also by measuring alarmin receptor
expression and response to inflammation in the CSCs as suggested in this work. In fact, a connection
between the hypoxia present in the growing GBM and the inflammation-related stimuli coming from
both the tumor-associated necrosis or originating from other brain regions, is still missing. To this effect,
in vitro and in vivo results, herewith reported, indicate that such connection requires the expression of
HIF-1α-dependent membrane receptors with an increase of tumor cancer cell migration and invasion.
4. Materials and Methods
4.1. Cell Lines and Hypoxia Treatments
Glioblastoma stem-like cells (GSCs) were isolated from surgical samples of adult GBM patients
(WHO grade IV) who had undergone complete or partial surgical resection at the Institute of
Neurosurgery, Catholic University School of Medicine in Rome, upon patient informed consent and
approval by the Institutional Ethics Committee of Fondazione Policlinico Gemelli, UCSC (Prot. 4720/17)
as previously described [35,38]. GSC cultures were established from surgical specimens through
mechanical dissociation and culturing in serum-free medium supplemented with 20 ng/mL epidermal
growth factor (EGF) and 10 ng/mL basic fibroblast growth factor (βFGF) (Peprotech, Rocky Hill, NY,
USA). Under these conditions, GSCs actively proliferate requiring 3–4 weeks to establish cell lines.
GSCs grow as spheroid clusters (tumorspheres) expressing stem cell markers, such as CD133, sex
determining region Y-box 2 (Sox2), Musashi-1 and Nestin [35,38]. The in vivo tumorigenic potential
of GSCs was assessed by intracranial or subcutaneous cell injection in immunocompromised mice,
resulting in tumors with the same antigen expression and histological tissue organization as the
human parent tumor. Four GSC lines (GSCs #1, #61, #83, #163) obtained from surgical specimens were
used in this study. Hypoxia was performed using a Hypoxic chamber (Modular Incubator Chamber,
Billups-Rothenberg, Del Mar, CA, USA). Cells were seeded in appropriate plates (6-well plate with lid,
flat bottom, ultra-low attachment surface, Costar) in the hood, then inserted, without lid, inside the
chamber in which a 1% oxygen gas solution has been fluxed in for 4 min. The sealed chamber was
placed in an incubator at 37 ◦C in 5% CO2 during the treatment. Where indicated, the same cells have
also been treated with digoxin (Sigma-Aldrich, Milan, Italy) and acriflavine (Sigma-Aldrich).
4.2. Necrotic Cell Extracts
Untreated GSCs have been used to obtain necrotic extracts. It is worth stressing, that, for us, it is not
important to know the exact composition of the necrotic extract. In fact, such necrotic extract can vary
from one cell type to another still maintaining its biochemical properties that are due to the presence of
alarmins. What is important is to demonstrate a general principle: necrosis is always accompanied by
release of alarmins that are recognized by surrounding cells through a series of different membrane
receptors that trigger an intracellular molecular signaling modifying cellular behavior. Briefly, cells
have been washed once or twice in phosphate buffered saline (PBS) (Sigma Aldrich) and the pellets
collected. For the preparation of whole cell extracts, cells were resuspended in a hypotonic solution
10 mM Tris–Cl pH 8.0, 1 mM KCl, 1.5 mM MgCl2, 0.1 mM DTT. Cells were then broken through a “freeze
and thaw” protocol (1 min in liquid nitrogen followed by 1 min at 37 ◦C, 4 times). Protein content was
determined by Bradford assay using BSA as standard (Biorad) and samples were stored at −80 ◦C.
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4.3. SDS-PAGE and Western Blot Analysis
Cells were centrifuged at 800× g for 10 min at 4 ◦C and pellet were resuspended in 100 µL of a
solution containing 50 mM Tris-Cl (Sigma-Aldrich), 250 mM sodium chloride (NaCl; Sigma-Aldrich),
5 mM ethylene diamine tetraacetic acid (EDTA; Sigma-Aldrich), 0.1% Triton® X-100 and 0.1 mM
Dithiothreitol (DTT, Sigma-Aldrich) plus 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich),
Protease inhibitor cocktail (PI; Sigma-Aldrich), 1 mM sodium orthovanadate (NA3VO4; Sigma-Aldrich)
and 10 mM sodium fluoride (NaF; Sigma-Aldrich) (lysis buffer). After 10 min on ice, samples were
centrifuged at 14,000× g for 10 min at 4 ◦C and the supernatants were collected. Protein concentration
was determined by the Bradford assay (Bio-Rad, Milan, Italy). Clarified protein lysates (40 µg) were
boiled for 5 min, electrophoresed onto denaturating SDS-PAGE gel and transferred onto a nitrocellulose
membrane (Bio-Rad). The blotting membranes were blocked with 5% non-fat dry milk (Bio-Rad)
for 1 h RT and then incubated with primary antibody overnight at 4 ◦C. Antibodies used were as
follows: HIF-1α (BD Transduction Lab), VEGF (Abcam, Cambridge, UK), Hexokinase 2 (Santa Cruz
Biotechnology, Heidelberg, DE), CDK4 (Santa Cruz Biotechnology). The following day, membranes
were washed three-times with 0.1% Tween® 20 (Sigma-Aldrich) in PBS (PBST) for 30 min at RT and
incubated with the appropriate secondary antibody for 1 h at RT. After another 3 washes in PBST,
the detection of the relevant protein was assessed by enhanced chemiluminescence (Lite Ablot® TURBO;
Euro Clone, Milan, Italy). Densitometric analysis of the bands, relative to CDK4, was performed using
Image J Software v1.51 (NIH, Bethesda, MD, USA).
4.4. Real-Time PCR Analysis
GSCs under normoxic and hypoxic conditions at different time points were collected and
washed. TRI Reagent® was added to cells and lysed using a syringe. Lysates were then centrifuged
(12,000 rpm/10 min/4 ◦C). One fifth of the initial TRI Reagent® volume of chloroform, has been
added for 5 min at room temperature. After another centrifugation, three different section have been
obtained, and RNA in the supernatant has been separated by the other components and transferred
in another 1.5 mL tube. Subsequently, glycogen is added to the supernatant together with half of
the initial TRI Reagent® volume of isopropyl alcohol (isopropanol) at room temperature for 10 min.
After centrifugation, the pellet has been washed with ethanol to obtain pure RNA. Following ethanol
evaporation, RNA pellet has been resuspended in bidistilled water (ddH2O) and quantified by
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Rome, Italy). Preamplification system
was used to reverse transcribe total RNA (1 µg) into complementary DNA according to manufacturer’s
instructions (Invitrogen, Milan, Italy). Real time (RT-PCR) amplification was carried out in the 7000
Real-time PCR system (Applied Biosystems, Foster City, CA, USA) using Real time SyBr Green qPCR
Superscript (Invitrogen, Milan, Italy). All reactions were carried out in triplicate.
4.5. Immunofluorescence Assays
GSCs, treated as described above, were collected in 15 mL tubes using a plastic monouse Pasteur
pipette and washed in cold PBS. GSCs were washed and centrifuged three times at 4 ◦C to remove all
the medium. Paraformaldehyde 3.7% was then added for 24 h at 4 ◦C. Subsequently, paraformaldehyde
was removed and cells were washed twice with cold PBS. Permeabilization was obtained using 1%
Triton® X-100 (Sigma Aldrich) for 10 min and after two additional washes, cells were incubated with
RAGE (Santa Cruz Biotechnology) primary antibody for 24 h at 4 ◦C. Subsequently, cells were washed
for three times and incubated with secondary antibody Alexa Fluor® 488 or Alexa Fluor® 555 for 2 h.
After two additional washes in PBS, cells were resuspended in 70% glycerol and mounted on frosted
microscope slides, ground 90◦ (Thermo Scientific). Fluorescence was observed by LSM 510 confocal
microscope (Zeiss, Varese, Italy).
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4.6. Cellular Invasion
Invasion of GSCs was determined using the Cell Invasion Assay (Chemicon, Milan, Italy) and
following manufacturer’s instructions. Briefly, the assay is composed of an Invasion Chamber, a 24-well
tissue culture plate, with 12 cell culture inserts. The insert contains 8 µm pore size polycarbonate
membrane, over which a thin layer of ECMatrix™ is dried. The ECM layer occludes the membranes
pores, blocking non-invasive cells from migrating through. Invasive cells on the other hand, migrate
through the ECM layer and cling to the bottom of polycarbonate membrane. Initially, 300 µL of
warm serum free medium have been added to rehydrate inserts for about 2 h. After rehydration,
medium has been gently removed from each insert and substituted with serum free medium containing
150,000 cells/point with or without 100 nM digoxin or 5 µM acriflavine for GSC #1, and 200 nM digoxin
or 10 µM acriflavine for GSC #83. At the same time, serum free medium with or without necrotic
extracts 1 µg/mL has been added to the bottom of the well. Hypoxic plates have been quickly put
inside the hypoxic chamber for 24 h. Subsequently, medium has been removed and the ECM has been
cleaned by using cotton swab. Invading cells have been stained by placing the insert into 500 µL of a
staining solution for 20 min. Subsequently, inserts have been dipped in a beaker of water several times
to remove the dye in excess. Cellular invasiveness has been quantified by dissolving stained cells in
10% acetic acid and transferring a consistent amount of the dye/solute mixture to a 96-well plate reader
(Promega, Milan, Italy) for colorimetric reading of OD at 560 nm.
4.7. Co-Culture Experiments
For these experiments we used GFP-expressing GSCs. Initially, HUVECs have been collected and
resuspended in an appropriate volume and stained with Calcein Red-Orange AM (Invitrogen). Cells
were plated on coverslips in growth medium for 24 h in the presence or absence of necrotic extracts
(1 µg/mL). Meanwhile, GFP-GSCs have been treated with digoxin, or acriflavine in normoxic and
hypoxic conditions for 24 h. After this time, GFP-GSCs have been collected and plated in the same
wells with HUVEC for 24 h. Then, cells have been collected and washed. Glasses have been washed
twice and then mounted on microscope slides. Fluorescence was observed by LSM 510 confocal
microscope (Zeiss).
4.8. Measurement of Intracellular ROS
To determine the amount of ROS production, 2′,7′-dichlorfluorescein-diacetate (DCFH-DA) was
used. Following treatment cells were harvested by centrifugation at 1200 rpm for 5 min at room
temperature. The pellets were resuspended in 0.5 mL of cell culture media containing 50 µM DCFH-DA
and incubated for 30 min at 37 ◦C in 5% CO2. Fluorescence intensity was measured by flow cytometry
(FACScalibur, BD Biosciences, San Jose, CA, USA).
4.9. In Vivo Experiments
Animal experiments have been performed in accordance to relevant institutional and national
regulations. Initially, we tested the efficacy of necrotic extracts to promote the inflammation by injecting
four different concentrations of necrotic extracts (5 ng/5 µL, 30 ng/5 µL, 60 ng/5 µL, 100 ng/5 µL) in the
brain of NOD/SCID mice (n, 6; 4–6 weeks of age; CD1 NOD-/SCID mice, Charles Rives, Italy). Two mice,
used as control, underwent a simple injection of the saline hypotonic buffer. Before grafting, mice
were anesthetized with intraperitoneal injection of diazepam (2 mg/100 g) followed by intramuscular
injection of ketamine (4 mg/100 g). The animal skulls were immobilized in a stereotactic head frame
and a burr hole will be made 2 mm right of the midline and 1 mm anterior to the coronal suture,
and cells slowly injected with a 10-µL Hamilton microsyringe placed at a depth of 3.5 mm from the
dura. The animal which received the highest dose of necrotic extracts (100 ng/5 µL) did not tolerate
treatment and were euthanized. After 2 weeks, the remaining mice were deeply anesthetized and
transcardially perfused with 0.1 M PBS (pH = 7.4), followed by 4% paraformaldehyde in 0.1 M PBS.
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After perfusion, the brains were removed from the skull and post-fixed in the same fixative overnight
at 4 ◦C. After rinsing in phosphate buffer, brains were cryoprotected in 15% sucrose solution followed
by a passage in 30% sucrose solution both overnight at 4 ◦C. Free-floating sections were then analyzed
for immunofluorescence. Sections were incubated in 10% normal horse serum in phosphate buffer
containing 0.2% Triton X-100 for 30 min to reduce non-specific binding. These sections were then
incubated with primary antibodies (GFAP, Chemicon, Milan, Italy; Iba1 Biocare Medical, Milan, Italy;
β-Tubulin III Merck/Millipore, Milan, Italy) diluted in phosphate buffer containing 2% normal horse
serum and 0.2% Triton X-100, overnight at 4 ◦C. After rinsing, the sections were incubated with labeled
secondary antibodies (Alexa Fluor Molecular Probes, Eugene, OR, USA) for 1 h at RT. After a thorough
rinse, the sections were incubated in phosphate buffer containing a Hoechst for 10 min at RT; sections
were mounted on slides and coverslipped with antifade medium. Images were obtained with a
Laser Scanning Confocal Microscope (Olympus FluoView FV1000, Olympus Inc, Melville, NY, USA).
Images were treated, analyzed and brain slices reconstructed by using Adobe Photoshop software and
fluorescence quantitation of histogram for the green channel was performed with ImageJ. To assess
whether necrotic extracts may stimulate migration of GSCs in established brain xenografts, mice were
first inoculated with GFP-GSCs following the procedure described above, 8 weeks later we inoculated
necrotic extracts in the contralateral brain hemisphere. Control mice received intracerebral injection
of hypotonic solution. Two weeks later, mice were sacrificed, their brains collected and analyzed as
described above.
4.10. Statistical Analysis
Statistically significant differences have been tested with the Student’s paired t test. p-values less
than 0.05 have been considered significant. All experiments have been performed in triplicate.
5. Conclusions
In this research paper, using in vitro and in vivo systems, we report that hypoxia and necrosis,
present in the tumor microenvironment, represent two fundamental stimuli for glioblastoma stem
cells (GSCs) migration. In fact, we showed that, in vitro, GSCs respond to hypoxia by increasing the
expression of HIF-1α and of alarmin receptor RAGE. Such a response, in turn, increases GSC migration
in the presence of necrotic stimulus. Moreover, such a situation is replicated in vivo where GSCs can
migrate from a brain hemisphere to the other in which a necrotic extract has been injected. Finally,
inhibition of the hypoxic response by digoxin and acriflavine prevented GSC response to hypoxia and
migration. Our findings suggest that the modulation of both hypoxic response and inflammation may
represent a valid strategy for reducing glioblastoma progression.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/8/2660/s1.
Figure S1: Evaluation of Digoxin and Acriflavine dosage.
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